CT 7439
Alternative Names: CT-7439Latest Information Update: 30 Sep 2024
Price :
$50 *
At a glance
- Originator Carrick Therapeutics
- Class Antineoplastics
- Mechanism of Action CDK13 protein inhibitors; Cyclin dependent kinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 16 Aug 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT06600789)
- 16 Aug 2024 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT06600789)
- 07 Sep 2023 Carrick Therapeutics plans a phase I trial in Solid tumours (Late stage disease) (PO) in 1H of 2024